BlackRock, Inc. 13D and 13G filings for Vaxcyte, Inc.:
- Schedule 13D must be filed within ten days after a person or an organization acquires beneficial ownership of more than 5% of a voting class of a company's equity securities.
- Shares have been adjusted for stock splits.
| Reported DateTime |
Transaction Date |
Type | Company Symbol |
Filed By Symbol |
Shares Owned % Owned |
Shares Vs. Prev Report | View |
| 2025-04-17 09:35 am Purchase |
2025-03-31 | 13G | Vaxcyte, Inc. PCVX |
BlackRock Inc. BLK |
9,825,638 7.600% |
1,250,400 (+14.58%) |
Filing |
| 2024-01-25 1:48 pm Purchase |
2023-12-31 | 13G | Vaxcyte, Inc. PCVX |
BlackRock Inc. BLK |
8,575,238 9.000% |
3,469,868 (+67.97%) |
Filing |
| 2023-02-03 12:10 pm Purchase |
2022-12-31 | 13G | Vaxcyte, Inc. PCVX |
BlackRock Inc. BLK |
5,105,370 6.500% |
2,316,363 (+83.05%) |
Filing |
| 2022-03-09 5:18 pm Purchase |
2022-02-28 | 13G | Vaxcyte, Inc. PCVX |
BlackRock Inc. BLK |
2,789,007 5.000% |
11,960 (+0.43%) |
Filing |
| 2022-02-04 4:12 pm Purchase |
2021-12-31 | 13G | Vaxcyte, Inc. PCVX |
BlackRock Inc. BLK |
2,777,047 5.300% |
2,777,047 (New Position) |
Filing |